Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The apolipoprotein E (APOE) e4 allele is the most prevalent genetic risk factor for Alzheimer's disease (AD). APOE e4 carriers suffer greater morbidity from head trauma, stroke, and carbon monoxide poisoning, yet possible interactions between APOE genotype and cancer therapy on cognition are unclear. Neuropathological and biomarker studies of young asymptomatic APOE e4 carriers that show elevated neocortical amyloid and medial temporal neurofibrillary tangles and longitudinal neuropsychological studies that show accelerated memory decline beginning around age 55-60 years define preclinical AD and have set the stage for assessing the potential adverse cognitive effects of cancer therapy in APOE e4 carriers.

Original languageEnglish (US)
Pages (from-to)1739-1742
Number of pages4
JournalPediatric Blood and Cancer
Volume61
Issue number10
DOIs
StatePublished - 2014

Fingerprint

Disease Susceptibility
Apolipoprotein E4
Apolipoproteins E
Alzheimer Disease
Genes
Neoplasms
Carbon Monoxide Poisoning
Therapeutics
Neurofibrillary Tangles
Cognitive Therapy
Craniocerebral Trauma
Amyloid
Longitudinal Studies
Biomarkers
Stroke
Alleles
Genotype
Morbidity

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy? / Caselli, Richard John.

In: Pediatric Blood and Cancer, Vol. 61, No. 10, 2014, p. 1739-1742.

Research output: Contribution to journalArticle

@article{78db9c779f574ac58909e6626a5689bc,
title = "Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?",
abstract = "The apolipoprotein E (APOE) e4 allele is the most prevalent genetic risk factor for Alzheimer's disease (AD). APOE e4 carriers suffer greater morbidity from head trauma, stroke, and carbon monoxide poisoning, yet possible interactions between APOE genotype and cancer therapy on cognition are unclear. Neuropathological and biomarker studies of young asymptomatic APOE e4 carriers that show elevated neocortical amyloid and medial temporal neurofibrillary tangles and longitudinal neuropsychological studies that show accelerated memory decline beginning around age 55-60 years define preclinical AD and have set the stage for assessing the potential adverse cognitive effects of cancer therapy in APOE e4 carriers.",
author = "Caselli, {Richard John}",
year = "2014",
doi = "10.1002/pbc.24768",
language = "English (US)",
volume = "61",
pages = "1739--1742",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?

AU - Caselli, Richard John

PY - 2014

Y1 - 2014

N2 - The apolipoprotein E (APOE) e4 allele is the most prevalent genetic risk factor for Alzheimer's disease (AD). APOE e4 carriers suffer greater morbidity from head trauma, stroke, and carbon monoxide poisoning, yet possible interactions between APOE genotype and cancer therapy on cognition are unclear. Neuropathological and biomarker studies of young asymptomatic APOE e4 carriers that show elevated neocortical amyloid and medial temporal neurofibrillary tangles and longitudinal neuropsychological studies that show accelerated memory decline beginning around age 55-60 years define preclinical AD and have set the stage for assessing the potential adverse cognitive effects of cancer therapy in APOE e4 carriers.

AB - The apolipoprotein E (APOE) e4 allele is the most prevalent genetic risk factor for Alzheimer's disease (AD). APOE e4 carriers suffer greater morbidity from head trauma, stroke, and carbon monoxide poisoning, yet possible interactions between APOE genotype and cancer therapy on cognition are unclear. Neuropathological and biomarker studies of young asymptomatic APOE e4 carriers that show elevated neocortical amyloid and medial temporal neurofibrillary tangles and longitudinal neuropsychological studies that show accelerated memory decline beginning around age 55-60 years define preclinical AD and have set the stage for assessing the potential adverse cognitive effects of cancer therapy in APOE e4 carriers.

UR - http://www.scopus.com/inward/record.url?scp=84908499764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908499764&partnerID=8YFLogxK

U2 - 10.1002/pbc.24768

DO - 10.1002/pbc.24768

M3 - Article

VL - 61

SP - 1739

EP - 1742

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 10

ER -